|
시장보고서
상품코드
2089826
POC(Point of Care) 분자진단 시장 : 시장 규모, 점유율, 동향 분석(용도별, 기술별, 검사 장소별, 최종 용도별, 지역별), 부문별 예측(2026-2033년)Point-of-Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing), By Technology, By Test Location, By End Use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
POC(Point of Care) 분자진단 시장 개요
세계의 POC(Point of Care) 분자진단 시장 규모는 2025년에 87억 3,000만 달러로 평가되었고 2026년 92억 8,000만 달러에서 2033년까지 144억 7,000만 달러로 성장하여 2026년부터 2033년까지 연평균 복합 성장률(CAGR)은 6.56%를 나타낼 것으로 예측됩니다.
북미는 세계 시장을 주도하고 있으며, 2025년에는 45.41%라는 가장 높은 매출 점유율을 기록했습니다. 이 시장은 환자 곁에서 신속하고 정확한 분자 검사를 수행하는 데 중점을 두고 있으며, 이를 통해 적시에 임상적 판단을 내릴 수 있게 해줍니다.
이러한 플랫폼은 감염병 검출, 호흡기 질환, 성병 등 다양한 용도로 활용되고 있습니다.
POC(Point of Care) 분자진단 시장을 형성하는 주요 동향
휴대용·카트리지식 시스템 :
컴팩트한 올인원 분자 검사 플랫폼은 독립형 카트리지를 갖추고 있어, 사용 편의성, 최소한의 교육 요건, 분산형 환경에 대한 적응성 덕분에 인기가 높아지고 있습니다.
다중 검사 기능 :
단일 검체에서 여러 병원체를 검출할 수 있는 PoC 기기의 도입이 확대되고 있습니다. 이를 통해, 특히 증상이 겹치는 호흡기 감염증의 경우, 보다 신속한 감별 진단이 가능해집니다.
디지털 헬스 생태계와의 통합 :
POC(Point of Care) 분자진단 장비에는 무선 연결 기능을 갖춘 설계가 점점 더 많이 채택되고 있으며, 이를 통해 전자 진료 기록과의 실시간 데이터 공유가 가능해져 원격 의료 및 원격 모니터링 활동을 지원하고 있습니다.
감염병 이외의 분야로의 확대 :
감염병 검사가 주류를 이루고 있는 한편, 각 기업은 종양학, 유전자 스크리닝, 항생제 내성 등 새로운 분야로 사업을 확장하며 POC(Point of Care) 분자진단 플랫폼의 임상적 유용성을 넓혀가고 있습니다.
자원이 부족한 지역 및 외딴 지역에 대한 집중 :
인프라 요건을 최소화한 견고한 배터리 구동형 기기의 개발을 통해, 특히 개발도상국의 농촌 지역, 응급 현장 및 이동형 의료 환경에서 진단 격차 해소가 추진되고 있습니다.
이러한 동향은 임상적 의사결정 과정에서 신속하고 분산된 진단이 점점 더 중요해지고 있음을 여실히 보여주고 있습니다. 휴대성, 연결성, 검사의 범용성이 지속적으로 향상됨에 따라, POC(Point of Care) 분자진단은 다양한 의료 환경에서 더욱 활용하기 쉬워지고 있습니다. 감염병 이외의 분야로 확대됨에 따라 그 임상적 의의가 더욱 넓어지고 있습니다. 의료 시스템이 속도와 정확성을 우선시하는 가운데, 이러한 기술에 대해서는 선진국과 개발도상국 모두에서 지속적인 수요가 예상됩니다.
자주 묻는 질문
목차
제1장 분석 방법 및 범위
제2장 주요 요약
제3장 시장 변동 요인, 동향 및 범위
제4장 기술별 비즈니스 분석
제5장 용도별 비즈니스 분석
제6장 검사 장소별 비즈니스 분석
제7장 최종 용도별 비즈니스 분석
제8장 지역별 비즈니스 분석
제9장 경쟁 구도
KTHPoint-of-Care Molecular Diagnostics Market Summary
The global point-of-care molecular diagnostics market size was valued at USD 8.73 billion in 2025 and is projected to grow from USD 9.28 billion in 2026 to USD 14.47 billion by 2033, at a CAGR of 6.56% from 2026 to 2033. North America dominated the global market and accounted for the largest revenue share of 45.41% in 2025. This market focuses on rapid, accurate molecular testing performed near the patient, enabling timely clinical decision-making.
These platforms are used across various applications, particularly in infectious disease detection, respiratory illnesses, and sexually transmitted infections.
Key Trends Shaping the Point-of-Care (POC) Molecular Diagnostics Market
Portable and Cartridge-Based Systems:
Compact, all-in-one molecular testing platforms with self-contained cartridges are gaining popularity due to ease of use, minimal training requirements, and suitability for decentralized settings.
Multiplex Testing Capabilities:
There is growing adoption of POC devices capable of detecting multiple pathogens from a single sample. This supports faster differential diagnosis, particularly for respiratory infections with overlapping symptoms.
Integration with Digital Health Ecosystems:
POC molecular devices are increasingly being designed with wireless connectivity, enabling real-time data sharing with electronic health records and supporting telemedicine and remote monitoring initiatives.
Expansion Beyond Infectious Diseases:
While infectious disease testing dominates, companies are expanding into new areas such as oncology, genetic screening, and antimicrobial resistance, broadening the clinical utility of POC molecular platforms.
Focus on Low-Resource and Remote Settings:
The development of rugged, battery-powered devices with minimal infrastructure needs is addressing diagnostic gaps in rural, emergency, and mobile care environments, especially in developing countries.
These trends underscore the growing importance of rapid, decentralized diagnostics in clinical decision-making. With continued improvements in portability, connectivity, and test versatility, point-of-care molecular diagnostics are becoming more accessible across diverse healthcare environments. The expansion beyond infectious diseases further broadens their clinical relevance. As healthcare systems prioritize speed and accuracy, these technologies are expected to see sustained demand in developed and developing regions.
Global Point-of-Care Molecular Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global point-of-care molecular diagnostics market report on the basis of application, technology, test location, end use, and region:
- Technology Outlook (Revenue, USD Billion, 2021 - 2033)
- PCR-based
- Genetic Sequencing-based
- Hybridization-based
- Microarray-based
- Application Outlook (Revenue, USD Billion, 2021 - 2033)
- Infectious Diseases
- HIV POC
- Clostridium difficile POC
- HBV POC
- Pneumonia or Streptococcus associated infections
- Respiratory syncytial virus (RSV) POC
- HPV POC
- Influenza/Flu POC
- HCV POC
- MRSA POC
- TB and drug-resistant TB POC
- HSV POC
- Other Infectious Diseases
- Oncology
- Hematology
- Prenatal Testing
- Endocrinology
- Other Applications
- Test Location Outlook (Revenue, USD Billion, 2021 - 2033)
- OTC
- POC
- End Use Outlook (Revenue, USD Billion, 2021 - 2033)
- Decentralized Labs
- Hospitals
- Home-care
- Assisted Living Healthcare Facilities
- Others
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Application Segment
- 1.1.1.2. Type Segment
- 1.1.1.3. Technology Segment
- 1.1.1.4. Test Location Segment
- 1.1.1.5. End Use Segment
- 1.1.1. Segment Definitions
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.3.1. Objectives
- 1.3.2. Objective - 1
- 1.3.3. Objective - 2
- 1.3.4. Objective - 3
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information or Data Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Validation
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. List of Abbreviations
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Technology & Application Snapshot
- 2.3. Test Location & Type Snapshot
- 2.4. End Use Snapshot
- 2.5. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers
- 3.4.1. Growing Demand for Rapid and Decentralized Testing
- 3.4.2. Rising Prevalence of Infectious Diseases
- 3.4.3. Technological Advancements in Molecular Platforms
- 3.5. Market Restraint Analysis
- 3.5.1. High Cost of Molecular POC Devices and Consumables
- 3.5.2. Regulatory and Quality Assurance Challenges
- 3.6. Business Environment Analysis
- 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
- 3.6.2. Porter's Five Forces Analysis
- 3.6.3. COVID-19 Impact Analysis
Chapter 4. Technology Business Analysis
- 4.1. Point-of-Care Molecular Diagnostics market: Technology Movement Analysis
- 4.2. PCR-based
- 4.2.1. PCR-based Market, 2021 - 2033 (USD Billion)
- 4.3. Genetic Sequencing-based
- 4.3.1. Genetic Sequencing-based Market, 2021 - 2033 (USD Billion)
- 4.4. Hybridization-based
- 4.4.1. Hybridization-based Market, 2021 - 2033 (USD Billion)
- 4.5. Microarray-based
- 4.5.1. Microarray-based Market, 2021 - 2033 (USD Billion)
Chapter 5. Application Business Analysis
- 5.1. Point-of-Care Molecular Diagnostics Market: Application Movement Analysis
- 5.2. Infectious Diseases
- 5.2.1. Infectious Diseases Market, 2021 - 2033 (USD Billion)
- 5.2.2. HIV POC
- 5.2.2.1. HIV POC Market, 2021 - 2033 (USD Billion)
- 5.2.3. Clostridium difficile POC
- 5.2.3.1. Clostridium difficile POC Market, 2021 - 2033 (USD Billion)
- 5.2.4. HBV POC
- 5.2.4.1. HBV POC Market, 2021 - 2033 (USD Billion)
- 5.2.5. Pneumonia or Streptococcus associated infections
- 5.2.5.1. Pneumonia or Streptococcus associated infections Market, 2021 - 2033 (USD Billion)
- 5.2.6. Respiratory Syncytial Virus (RSV) POC
- 5.2.6.1. Respiratory Syncytial Virus (RSV) POC Market, 2021 - 2033 (USD Billion)
- 5.2.7. HPV POC
- 5.2.7.1. HPV POC Market, 2021 - 2033 (USD Billion)
- 5.2.8. Influenza/Flu POC
- 5.2.8.1. Influenza/Flu POC Market, 2021 - 2033 (USD Billion)
- 5.2.9. HCV POC
- 5.2.9.1. HCV POC Market, 2021 - 2033 (USD Billion)
- 5.2.10. MRSA POC
- 5.2.10.1. MRSA POC Market, 2021 - 2033 (USD Billion)
- 5.2.11. TB and drug-resistant TB POC
- 5.2.11.1. TB and drug-resistant TB POC Market, 2021 - 2033 (USD Billion)
- 5.2.12. HSV POC
- 5.2.12.1. HSV POC Market, 2021 - 2033 (USD Billion)
- 5.2.13. Other Infectious Diseases
- 5.2.13.1. Other Infectious Diseases Market, 2021 - 2033 (USD Billion)
- 5.3. Oncology
- 5.3.1. Oncology Market, 2021 - 2033 (USD Billion)
- 5.4. Hematology
- 5.4.1. Hematology Market, 2021 - 2033 (USD Billion)
- 5.5. Prenatal Testing
- 5.5.1. Prenatal Testing Market, 2021 - 2033 (USD Billion)
- 5.6. Endocrinology
- 5.6.1. Endocrinology Market, 2021 - 2033 (USD Billion)
- 5.7. Others
- 5.7.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 6. Test Location Business Analysis
- 6.1. Point-of-Care Molecular Diagnostics Market: Test Location Movement Analysis
- 6.2. OTC
- 6.2.1. OTC Market, 2021 - 2033 (USD Billion)
- 6.3. POC
- 6.3.1. POC Market, 2021 - 2033 (USD Billion)
Chapter 7. End Use Business Analysis
- 7.1. Point-of-Care Molecular Diagnostics Market: End Use Movement Analysis
- 7.2. Decentralized Labs
- 7.2.1. Decentralized Labs Market, 2021 - 2033 (USD Billion)
- 7.3. Hospitals
- 7.3.1. Hospitals Market, 2021 - 2033 (USD Billion)
- 7.4. Homecare
- 7.4.1. Home-care Market, 2021 - 2033 (USD Billion)
- 7.5. Assisted Living Healthcare Facilities
- 7.5.1. Assisted Living Healthcare Facilities Market, 2021 - 2033 (USD Billion)
- 7.6. Others
- 7.6.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 8. Regional Business Analysis
- 8.1. Point-of-Care Molecular Diagnostics Market Share By Region, 2025 & 2033
- 8.2. North America
- 8.2.1. North America Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.2.2. U.S.
- 8.2.2.1. Key Country Dynamics
- 8.2.2.2. Target Disease Prevalence
- 8.2.2.3. Competitive Scenario
- 8.2.2.4. Regulatory Framework
- 8.2.2.5. Reimbursement Scenario
- 8.2.2.6. U.S. Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD BILLION)
- 8.2.3. Canada
- 8.2.3.1. Key Country Dynamics
- 8.2.3.2. Target Disease Prevalence
- 8.2.3.3. Competitive Scenario
- 8.2.3.4. Regulatory Framework
- 8.2.3.5. Reimbursement Scenario
- 8.2.3.6. Canada Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.2.4. Mexico
- 8.2.4.1. Key Country Dynamics
- 8.2.4.2. Target Disease Prevalence
- 8.2.4.3. Competitive Scenario
- 8.2.4.4. Regulatory Framework
- 8.2.4.5. Reimbursement Scenario
- 8.2.4.6. Mexico Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.3. Europe
- 8.3.1. Europe Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.3.2. Germany
- 8.3.2.1. Key Country Dynamics
- 8.3.2.2. Target Disease Prevalence
- 8.3.2.3. Competitive Scenario
- 8.3.2.4. Regulatory Framework
- 8.3.2.5. Reimbursement Scenario
- 8.3.2.6. Germany Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.3.3. UK
- 8.3.3.1. Key Country Dynamics
- 8.3.3.2. Target Disease Prevalence
- 8.3.3.3. Competitive Scenario
- 8.3.3.4. Regulatory Framework
- 8.3.3.5. Reimbursement Scenario
- 8.3.3.6. UK Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.3.4. France
- 8.3.4.1. Key Country Dynamics
- 8.3.4.2. Target Disease Prevalence
- 8.3.4.3. Competitive Scenario
- 8.3.4.4. Regulatory Framework
- 8.3.4.5. Reimbursement Scenario
- 8.3.4.6. France Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.3.5. Italy
- 8.3.5.1. Key Country Dynamics
- 8.3.5.2. Target Disease Prevalence
- 8.3.5.3. Competitive Scenario
- 8.3.5.4. Regulatory Framework
- 8.3.5.5. Reimbursement Scenario
- 8.3.5.6. Italy Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.3.6. Spain
- 8.3.6.1. Key Country Dynamics
- 8.3.6.2. Target Disease Prevalence
- 8.3.6.3. Competitive Scenario
- 8.3.6.4. Regulatory Framework
- 8.3.6.5. Reimbursement Scenario
- 8.3.6.6. Spain Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.3.7. Denmark
- 8.3.7.1. Key Country Dynamics
- 8.3.7.2. Target Disease Prevalence
- 8.3.7.3. Competitive Scenario
- 8.3.7.4. Regulatory Framework
- 8.3.7.5. Reimbursement Scenario
- 8.3.7.6. Denmark Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.3.8. Sweden
- 8.3.8.1. Key Country Dynamics
- 8.3.8.2. Target Disease Prevalence
- 8.3.8.3. Competitive Scenario
- 8.3.8.4. Regulatory Framework
- 8.3.8.5. Reimbursement Scenario
- 8.3.8.6. Sweden Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.3.9. Norway
- 8.3.9.1. Key Country Dynamics
- 8.3.9.2. Target Disease Prevalence
- 8.3.9.3. Competitive Scenario
- 8.3.9.4. Regulatory Framework
- 8.3.9.5. Reimbursement Scenario
- 8.3.9.6. Norway Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.4.2. Japan
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Target Disease Prevalence
- 8.4.2.3. Competitive Scenario
- 8.4.2.4. Regulatory Framework
- 8.4.2.5. Reimbursement Scenario
- 8.4.2.6. Japan Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.4.3. China
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Competitive Scenario
- 8.4.3.4. Regulatory Framework
- 8.4.3.5. Reimbursement Scenario
- 8.4.3.6. China Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.4.4. India
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Competitive Scenario
- 8.4.4.4. Regulatory Framework
- 8.4.4.5. Reimbursement Scenario
- 8.4.4.6. India Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.4.5. South Korea
- 8.4.5.1. Key Country Dynamics
- 8.4.5.2. Target Disease Prevalence
- 8.4.5.3. Competitive Scenario
- 8.4.5.4. Regulatory Framework
- 8.4.5.5. Reimbursement Scenario
- 8.4.5.6. South Korea Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.4.6. Australia
- 8.4.6.1. Key Country Dynamics
- 8.4.6.2. Target Disease Prevalence
- 8.4.6.3. Competitive Scenario
- 8.4.6.4. Regulatory Framework
- 8.4.6.5. Reimbursement Scenario
- 8.4.6.6. Australia Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.4.7. Thailand
- 8.4.7.1. Key Country Dynamics
- 8.4.7.2. Target Disease Prevalence
- 8.4.7.3. Competitive Scenario
- 8.4.7.4. Regulatory Framework
- 8.4.7.5. Reimbursement Scenario
- 8.4.7.6. Thailand Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.5. Latin America
- 8.5.1. Latin America Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.5.2. Brazil
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Target Disease Prevalence
- 8.5.2.3. Competitive Scenario
- 8.5.2.4. Regulatory Framework
- 8.5.2.5. Reimbursement Scenario
- 8.5.2.6. Brazil Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.5.3. Argentina
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Competitive Scenario
- 8.5.3.4. Regulatory Framework
- 8.5.3.5. Reimbursement Scenario
- 8.5.3.6. Argentina Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.6. MEA
- 8.6.1. MEA Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.6.2. South Africa
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Target Disease Prevalence
- 8.6.2.3. Competitive Scenario
- 8.6.2.4. Regulatory Framework
- 8.6.2.5. Reimbursement Scenario
- 8.6.2.6. South Africa Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.6.3. Saudi Arabia
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Competitive Scenario
- 8.6.3.4. Regulatory Framework
- 8.6.3.5. Reimbursement Scenario
- 8.6.3.6. Saudi Arabia Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.6.4. UAE
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Target Disease Prevalence
- 8.6.4.3. Competitive Scenario
- 8.6.4.4. Regulatory Framework
- 8.6.4.5. Reimbursement Scenario
- 8.6.4.6. UAE Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
- 8.6.5. Kuwait
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Target Disease Prevalence
- 8.6.5.3. Competitive Scenario
- 8.6.5.4. Regulatory Framework
- 8.6.5.5. Reimbursement Scenario
- 8.6.5.6. Kuwait Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Billion)
Chapter 9. Competitive Landscape
- 9.1. Participant's overview
- 9.2. Financial performance
- 9.3. Participant categorization
- 9.3.1. Market Leaders
- 9.3.2. Point-of-Care Molecular Diagnostics Market Share Analysis, 2025
- 9.3.3. Company Profiles
- 9.3.3.1. Abbott
- 9.3.3.1.1. Company Overview
- 9.3.3.1.2. Financial Performance
- 9.3.3.1.3. Product Benchmarking
- 9.3.3.1.4. Strategic Initiatives
- 9.3.3.2. F. Hoffmann-La Roche AG
- 9.3.3.2.1. Company Overview
- 9.3.3.2.2. Financial Performance
- 9.3.3.2.3. Product Benchmarking
- 9.3.3.2.4. Strategic Initiatives
- 9.3.3.3. QIAGEN
- 9.3.3.3.1. Company Overview
- 9.3.3.3.2. Financial Performance
- 9.3.3.3.3. Product Benchmarking
- 9.3.3.3.4. Strategic Initiatives
- 9.3.3.4. Danaher Corporation
- 9.3.3.4.1. Company Overview
- 9.3.3.4.2. Financial Performance
- 9.3.3.4.3. Product Benchmarking
- 9.3.3.4.4. Strategic Initiatives
- 9.3.3.5. BIOMERIEUX
- 9.3.3.5.1. Company Overview
- 9.3.3.5.2. Financial Performance
- 9.3.3.5.3. Product Benchmarking
- 9.3.3.5.4. Strategic Initiatives
- 9.3.3.6. OraSure Technologies Inc.
- 9.3.3.6.1. Company Overview
- 9.3.3.6.2. Financial Performance
- 9.3.3.6.3. Product Benchmarking
- 9.3.3.6.4. Strategic Initiatives
- 9.3.3.7. binx health, inc.
- 9.3.3.7.1. Company Overview
- 9.3.3.7.2. Financial Performance
- 9.3.3.7.3. Product Benchmarking
- 9.3.3.7.4. Strategic Initiatives
- 9.3.3.8. QuidelOrtho Corporation.
- 9.3.3.8.1. Company Overview
- 9.3.3.8.2. Financial Performance
- 9.3.3.8.3. Product Benchmarking
- 9.3.3.8.4. Strategic Initiatives
- 9.3.3.1. Abbott
- 9.3.4. Strategy Mapping
- 9.3.4.1. Expansion
- 9.3.4.2. Acquisition
- 9.3.4.3. Collaborations
- 9.3.4.4. Disease Type/Drug Class Launch
- 9.3.4.5. Partnerships
- 9.3.4.6. Others
